Abstract
The Cooperative Study Group conducted a study to assess the therapeutic effects of chemoembolization in patients with advanced hepatocellular carcinoma (HCC) using either epirubicin hydrochloride (FARM) or doxorubicin hydrochloride (ADR). A total of 77 patients were enrolled in this study and randomized into 2 groups: 39 patients were treated with a FARM solution as the material for Lipiodol-transcatheter arterial embolization (TAE; FARM group), and 38 patients were treated with an ADR solution as the material for L-TAE (ADR group). For the FARM group, the 1-year survival rate was 69.9% and the 2-year survival rate was 44.5%. For the ADR group, the corresponding survival rates were 74.7% and 44.0%. The differences among the above figures were not statistically significant. As side effects, fever, nausea, and generalized fatigue occurred at almost the same frequencies in the two groups. Changes detected in the liver function and the peripheral blood cell count in both groups were not severe. There was no significant difference between the toxic effects observed in the two groups. In conclusion, there was no significant difference in therapeutic efficacy between the FARM and ADR groups.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Epirubicin Study Group for Hepatocellular Carcinoma (1987) Intra-arterial administration of epirubicin in the treatment of nonresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 19: 183
Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Mikuriya S, Monden M, Yumoto Y, Mori T, Oda T, the Cooperative Study Group for Liver Cancer Treatment of Japan (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of Lipiodol-transcatheter arterial embolization with and without Adriamycin (first cooperative study). Cancer Chemother Pharmacol 31 [Suppl I]: S1
Ohishi H, Yoshimura H, Uchida H, Sakaguchi H, Yoshioka T, Ohue S, Matsui T, Takaya A, Tsujii T (1989) Transcatheter arterial embolization using iodized oil (Lipiodol) mixed with an anti-cancer drug for the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 23 [Suppl]: S33
Okamura J, Kawai S, Ogawa M, Ohashi Y, Tani M, Inoue J, Kawarada Y, Kusano M, Kubo Y, Kuroda C, Sakata Y, Shimamura Y, Jinno K, Takahashi A, Takayasu K, Tamura K, Nagasue N, Nakanishi Y, Makino M, Masuzawa M, Mikuriya S, Monden M, Yumoto Y, Mori T, Oda T, the Cooperative Study Group for Liver Cancer Treatment of Japan (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of L-TAE with Farmorubicin and L-TAE with Adriamycin (second cooperative study). Cancer Chemother Pharmacol 31 [Suppl I]: S20
Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S (1987) Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 163: 345
Uchida H, Ohishi H, Matsuo N, Nishimine K, Ohue S, Nishimura Y, Maeda M, Yoshioka T (1990) Transcatheter hepatic segmental arterial embolization using Lipiodol mixed with an anticancer drug and Gelfoam particles for hepatocellular carcinoma. Cardiovasc Intervent Radiol 13: 140
Yodono H, Saito Y, Saikawa Y, Midorikawa H, Yokoyama Y, Takekawa S (1989) Combination chemoembolization therapy for hepatocellular carcinoma, mainly using cisplatin (CDDP). Cancer Chemother Pharmacol 23 [Suppl]: S42
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Watanabe, S., Nishioka, M., Ohta, Y. et al. Prospective and randomized controlled study of chemoembolization therapy in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 33 (Suppl 1), S93–S96 (1994). https://doi.org/10.1007/BF00686676
Issue Date:
DOI: https://doi.org/10.1007/BF00686676